Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Ocular Therapeutix, Inc.

Market Cap 2.11B 1.82B 1.67B 1.58B 2.96B 199B 2.99B 19.84B 7.72B 97.77B 7.92B 7.75B 338B P/E 2026 *
-6.03x
P/E 2027 * -6.88x
Enterprise Value 1.75B 1.51B 1.39B 1.3B 2.45B 165B 2.47B 16.43B 6.4B 80.95B 6.56B 6.42B 280B EV / Sales 2026 *
33.7x
EV / Sales 2027 * 17.2x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocular Therapeutix, Inc.

1 day-1.50%
1 week+8.22%
Current month+4.50%
1 month+12.35%
3 months+10.90%
6 months-27.47%
Current year-22.45%
1 week 8.62
Extreme 8.6188
10.39
1 month 7.86
Extreme 7.86
10.39
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 2024-04-14
Director of Finance/CFO 50 2026-01-19
Chief Tech/Sci/R&D Officer 49 2024-05-19
Director TitleAgeSince
Chairman 57 2019-06-30
Director/Board Member 78 2012-11-04
Director/Board Member 66 2019-03-19
Date Insider Type Main position Quantity % Market Cap.
06-09Free

Director

58,000 0.0274%
06-09Free

Director

58,000 0.0274%
06-09Free

Executive/Senior Manager

29,465 0.0139%
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%+8.22%+13.03%+102.04% 2.11B
-1.95%-5.58%+39.63%+142.54% 992B
-2.70%-4.24%+51.42%+39.05% 564B
-2.43%-4.00%+16.32%+56.56% 391B
-2.82%+0.68%+24.66%+16.53% 330B
-2.57%-3.03%+24.83%+13.06% 280B
-2.24%-2.57%+24.69%+30.35% 279B
-1.91%-0.87%-41.95%-48.26% 196B
-1.83%-5.28%+15.79%+46.71% 184B
-2.23%-2.45%+13.69%+58.01% 156B
Average -2.16%+1.40%+18.21%+45.66% 337.33B
Weighted average by Cap. -2.23%-0.48%+27.71%+62.68%

Financials

2026 *2027 *
Net sales 51.91M 44.78M 41.17M 38.75M 72.82M 4.9B 73.43M 488M 190M 2.4B 195M 191M 8.32B 122M 105M 96.38M 90.71M 170M 11.47B 172M 1.14B 445M 5.63B 456M 446M 19.47B
Net income -362M -312M -287M -270M -507M -34.12B -511M -3.4B -1.32B -16.74B -1.36B -1.33B -57.93B -329M -284M -261M -246M -462M -31.05B -465M -3.09B -1.2B -15.24B -1.23B -1.21B -52.72B
Net Debt -363M -313M -288M -271M -509M -34.26B -513M -3.41B -1.33B -16.81B -1.36B -1.33B -58.16B -18M -15.53M -14.28M -13.44M -25.25M -1.7B -25.46M -169M -65.87M -834M -67.56M -66.11M -2.88B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
26-06-18 9.440 $ -2.07% 2,531,691
26-06-17 9.640 $ +7.83% 7,403,976
26-06-16 8.940 $ -0.56% 2,329,712
26-06-15 8.990 $ +0.56% 2,467,340
26-06-12 8.940 $ +2.76% 2,696,811
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.640USD
Average target price
26.55USD
Spread / Average Target
+175.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!